I would read it that way. Why would you expand the study when so close to unblinding the P3 study unless you were observing some compelling improvements and wanted to be able to rapidly expand the target group.
Imagine if they could give Trofinetide when they begin to deteriorate not afterwards, they may be able to avoid much of the disability.That would be a wonderful outcome!
Ann: Trofinetide Rett syndrome clinical trial in girls aged 2-5, page-10
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.71 |
Change
-0.590(3.41%) |
Mkt cap ! $2.135B | |||
| Open | High | Low | Value | Volume |
| $17.50 | $17.55 | $16.57 | $10.01M | 594.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 598 | $16.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.87 | 1676 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |